<![endif]>rev: July 23, 2002
Return (alphabetical antibody index page)
Return (neurohistology ab index page)
(anti-Human and others as indicated)
RDI Division of Fitzgerald Industries Intl offers a wide line of antibodies. Since no one antibody works best for all applications (neutralization, blotting, histochemistry, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.
-see also N terminal antibody
Immunogen: Synthetic Peptide: 681 GYENPTYKFFEQMQN 695
Form: Whole serum
Supplied as: 0.25ml vials with 0.1% NaN3
Titer: Reported working dilution using neat serum:*
- ELISA using immunizing peptide: 1:25,000
- IHC using formalin-fixed, paraffin-embedded sections: N/D
- IHC using paraformaldehyde-fixed, frozen sections: N/D
-Western blots: 1:5,000
Specificity: Amino acid sequence 681-695 of human amyloid precursor protein.
Storage: Short term: Refrigerate at 4º C
Long term: Freeze at -20º C. (recommend aliquot and store
–20 DEG C, avoid frequent freeze thaw cycles
FOR RESEARCH AND MANUFACTURING USE ONLY
* Various assay conditions require that the optimum working concentrations be determined by serial dilutions of this product.
The amyloid precursor protein (APP) is a large membrane protein whose Cterminus projects into the extracellular space. In Alzheimer's disease (AD), the APP is proteolytically cleaved at the N-terminal of ABeta by Beta-secretase (BACE) to release a ~100 kD APPsbeta protein into the extracellular space. The remaining 12 kD fragment remains membrane bound where it can be cleaved at its C-terminus by ( -secretase (presenilins) to release the insoluble Abeta peptide into the extracellular space with the ~8 kD APP C-terminal fragment (CTFbeta) remaining membrane bound. The APP is the subject of intensive investigations to determine how this protein is broken down abnormally in AD brains to give rise to Abeta, which is present in senile plaques and vessels.
A goat antiserum to a synthetic peptide that corresponds to amino acids 681-695 of the C-terminus of human APP is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA. In western blots it immunolabels the APP holoprotein. The smaller CTFbeta is rapidly degraded and not detected on westerns. This antibody should be a valuable tool for scientists working to understand the role of in Alzheimer’s disease.
This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide. Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification. A control immune serum (Cat no. RDI-GPA018E $315.00/0.5ml) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no.RDI-AMYPREC-CPX, $312.00/1mg), which can be used to neutralize immunoreactivity.
Amyloid Precursor Protein C-terminal Peptide Antiserum
Cat No. RDI-AMYPRECabG ($315.00/250µl)
Western blot of neuronal cell lysate using Amyloid Precursor Protein C-terminalantiserum at 1:5,000 dilution.
For Research Use only
RDI Division of Fitzgerald Industries Intl
34 Junction Square Drive
Concord MA 01742-3049
phone (978) 371-6446 or (800) 370-2222
fax (978) 371-2266
RETURN (neurohistology ab page)
Return (alphabetical antibody page)